Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556785 | 0.89 | KMT2A (0.44) | HTR2AGRM2CCR3 | |
| Hydrochloric Acid SCHEMBL14633797 | 0.88 | KMT2A (0.44) | HTR2AGRM2CCR3 | |
| SCHEMBL2555053 | 0.86 | SSTR5 (0.42) | HTR2ADRD2SIGMAR1 | |
| SCHEMBL2553797 | 0.86 | CCR3 (0.47) | HTR2AKCNH2CCR3HTR4 | |
| Hydrochloric Acid SCHEMBL14633467 | 0.85 | KCNH2 (0.42) | KCNH2 | |
| Hydrochloric Acid SCHEMBL14633841 | 0.85 | CCR3 (0.46) | HTR2ACCR3HTR4 | |
| SCHEMBL2557120 | 0.81 | CCR3 (0.46) | HTR2ACCR3HTR4 | |
| Hydrochloric Acid SCHEMBL2554746 | 0.81 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL2554766 | 0.77 | DRD2 (0.45) | DRD2GRM2KCNH2HTR4 | |
| Hydrochloric Acid SCHEMBL14633419 | 0.76 | DRD2 (0.44) | DRD2GRM2KCNH2HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655906-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-05-23 | — | — | US | disclosed |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-9120801-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| EP-2556074-B1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | ACRAF (IT) | 2015-01-21 | — | — | EP | disclosed |
| EP-2556074-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. (IT) | 2013-01-24 | — | — | US | disclosed |
| WO-2011124430-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | HTR2A 1361/4885DRD2 1140/4885HRH1 450/4885 |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | HTR2A 1361/4885DRD2 1140/4885HRH1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.